Universität zu Köln

Zimmerman, Stefan, Das, Arundhati, Wang, Shuhang, Julian, Ricklie, Gandhi, Leena ORCID: 0000-0002-2398-9179 and Wolf, Juergen (2019). 2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer. J. Thorac. Oncol., 14 (5). S. 768 - 784. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Full text not available from this repository.

Abstract

SCLC remains an aggressive, deadly cancer with only modest effect on survival from standard chemotherapy. However, with the advent of immunotherapy and comprehensive genomic and transcriptomic profiling, multiple new targets are showing promise in the clinical arena, and just recently programmed death ligand 1 inhibition has been shown to improve the efficacy of standard chemotherapy in extended-disease SCLC. Our increasing understanding of the interactions between different pathways will enable more tailored immunotherapy and targeted therapies based on specific biomarkers and rational combinations. Here we discuss the preclinical and clinical strides in 2017 and 2018 that put us on the threshold of a new era in therapeutics and will, it is hoped, translate into significant improvements in survival. (C) 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Zimmerman, Stefan UNSPECIFIED UNSPECIFIED UNSPECIFIED Das, Arundhati UNSPECIFIED UNSPECIFIED UNSPECIFIED Wang, Shuhang UNSPECIFIED UNSPECIFIED UNSPECIFIED Julian, Ricklie UNSPECIFIED UNSPECIFIED UNSPECIFIED Gandhi, Leena UNSPECIFIED orcid.org/0000-0002-2398-9179 UNSPECIFIED Wolf, Juergen UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-149931
DOI:	10.1016/j.jtho.2019.01.022
Journal or Publication Title:	J. Thorac. Oncol.
Volume:	14
Number:	5
Page Range:	S. 768 - 784
Date:	2019
Publisher:	ELSEVIER SCIENCE INC
Place of Publication:	NEW YORK
ISSN:	1556-1380
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ANTIBODY-DRUG CONJUGATE; PROPHYLACTIC CRANIAL IRRADIATION; NIVOLUMAB PLUS IPILIMUMAB; PHASE-II TRIAL; OPEN-LABEL; AURORA KINASE; WEE1 KINASE; ROVALPITUZUMAB TESIRINE; MAINTENANCE THERAPY; 2ND-LINE THERAPY Multiple languages Oncology; Respiratory System Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/14993